The company’s executive team has considerable accomplishments:
Track record with successful commercial launch of over 300 drug products with revenues of $800 million
Generic drug savings to customers and patients exceeding $3 billion in discounts
Exceptional compliance record with the FDA and many other regulatory agencies (DEA, EPA, etc.)
No FDA warning letters
Successful remediation of previous management’s warnings letters and consent decrees
Creation of 500 US scientists jobs and employment of 400 ex-US pharmaceutical jobs
Founding, development, and sale of multiple pharmaceutical firms totaling $1.1 billion
Odin specializes in difficult-to-develop and difficult-to-manufacture sterile injectable and sterile ophthalmic products.
The privately-held company has its headquarters and development facility in Somerset, New Jersey.